Early and late erythropoietin do not alter oxygen induced retinopathy severity in a rat model of anemia
In a rat model of oxygen-induced retinopathy and anemia, neither early nor late erythropoietin administration altered the anatomical severity of retinopathy or produced clinically relevant molecular effects during anemia, although late erythropoietin did modulate inflammatory and transcriptomic pathways in non-anemic retinas.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
Premature birth often forces a baby's eyes to develop in an environment far different from the womb. Inside the uterus, the developing retina receives oxygen through the placenta, but once born, especially if born very early, the infant is exposed to the higher oxygen levels of the outside world. This sudden shift can disrupt the delicate growth of blood vessels in the eye. The condition, known as retinopathy of prematurity, involves a two-stage process: first, the high oxygen levels cause existing blood vessels to stop growing or die off, leaving parts of the retina without a blood supply; second, as the eye continues to mature, it desperately signals for new vessels to grow, often leading to a chaotic, disorganized network that can leak fluid or bleed, potentially causing blindness. To help premature infants who struggle with low red blood cell counts, doctors frequently administer a hormone called erythropoietin. This substance naturally stimulates the body to produce more red blood cells, reducing the need for blood transfusions. However, because erythropoietin also encourages blood vessel growth, scientists have long worried that giving it to these vulnerable infants might accidentally worsen the eye disease, either by fueling the chaotic new growth or by failing to protect the eye at the right time.
Researchers at the University of Minnesota Medical School set out to untangle this complex relationship by creating a precise model in newborn rats. They simulated the harsh conditions of a premature birth by exposing the pups to cycles of high and low oxygen, a method that reliably triggers the same eye disease seen in human infants. To mimic the anemia common in premature babies, the team regularly removed small amounts of blood from some of the pups, lowering their red blood cell counts to a specific, low range. They then divided these animals into groups to test the effects of erythropoietin given at different times. One group received the hormone starting immediately after birth and continuing for most of the study, representing early treatment. Another group received it only after the first week, representing late treatment. A control group received a harmless saline solution instead. The scientists waited until the pups were twenty days old, a point when the eye disease is fully active, to examine the health of their retinas.
The results offered a clear, if somewhat surprising, picture of how the hormone interacts with anemia and eye disease. The team found that the anemia itself actually made the eye disease less severe. The pups with low red blood cell counts had smaller areas of missing blood vessels and significantly fewer bleeding spots in their eyes compared to the non-anemic pups. This suggests that the lack of oxygen caused by anemia might paradoxically protect the eye from the most damaging phase of the disease. When the researchers added erythropoietin to the mix, the outcome depended heavily on whether the animal was anemic. In the anemic pups, the hormone did almost nothing. Whether given early or late, it did not change the size of the damaged areas in the eye, nor did it alter the molecular signals that drive the disease. The hormone simply failed to make a difference in the context of existing anemia.
The story changed slightly for the pups that were not anemic. In these animals, giving the hormone late in the development process did not change the overall severity of the eye disease, but it did trigger a cascade of changes inside the cells. The late treatment reduced the number of bleeding spots in the eye and lowered levels of several proteins that signal inflammation. However, this apparent benefit came with a complex molecular cost. The hormone switched on genes associated with cell death and turned off genes responsible for building healthy blood vessels. While the bleeding decreased, the underlying genetic instructions suggested the eye was under significant stress and that its ability to repair itself was being hindered. In the anemic pups, none of these molecular shifts occurred; the hormone was essentially invisible to the retina's genetic machinery.
The study concludes that for premature infants who are anemic, the timing of erythropoietin treatment—whether started early or late—does not appear to alter the severity of the eye disease. The hormone did not make the condition worse, but it also did not provide the protective benefits seen in non-anemic eyes. The researchers noted that while late treatment reduced bleeding in non-anemic animals, the accompanying genetic changes involving cell death and inhibited vessel growth warrant caution. Ultimately, the findings suggest that the presence of anemia fundamentally changes how the eye responds to this hormone, and that in the specific context of anemia, the drug exerts little to no clinically relevant effect on the development of retinopathy. The work highlights that the biological environment of the patient, specifically their red blood cell count, is a critical factor in determining how the eye reacts to treatment.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.